Blautia wexlerae
Selected indexed studies
- Oral administration of Blautia wexlerae ameliorates obesity and type 2 diabetes via metabolic remodeling of the gut microbiota. (Nat Commun, 2022) [PMID:35982037]
- Potential Applications of Blautia wexlerae in the Regulation of Host Metabolism. (Probiotics Antimicrob Proteins, 2024) [PMID:38703323]
- Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. (Nat Med, 2025) [PMID:40200054]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Commensal bacteria promote azathioprine therapy failure in inflammatory bowel disease via decreasing 6-mercaptopurine bioavailability. (2023) pubmed
- Oral administration of Blautia wexlerae ameliorates obesity and type 2 diabetes via metabolic remodeling of the gut microbiota. (2022) pubmed
- Potential Applications of Blautia wexlerae in the Regulation of Host Metabolism. (2024) pubmed
- Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. (2025) pubmed
- Gut Microbiome in Progressive Multiple Sclerosis. (2021) pubmed
- Gut microbiota signatures of vulnerability to food addiction in mice and humans. (2024) pubmed
- Effects of acetate-producing Blautia wexlerae on oxidative stress and NLRP3 inflammasome in obesity-associated male infertility. (2024) pubmed
- A functional Wood-Ljungdahl pathway devoid of a formate dehydrogenase in the gut acetogens Blautia wexlerae, Blautia luti and beyond. (2022) pubmed
- Blautia wexlerae Transforms Dietary Fatty Acids to Activate Enteroendocrine Signaling and Improve Metabolic Health in Mice and Humans. (2026) pubmed
- Quantification of Blautia wexlerae and Blautia luti in human faeces by real-time PCR using specific primers. (2015) pubmed